2,869
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 13:11, 15 September 2023
, 15 September 2023→Studies
| Line 91: | Line 91: | ||
|- | |- | ||
|Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550608/</ref> | |Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550608/</ref> | ||
| | |[[RCT]], 10 weeks | ||
* placebo (n=12) | |||
* 250 mg/day (n=13) | |||
| | | | ||
* 25 postmenopausal women with prediabetes | * 25 postmenopausal women with prediabetes | ||
| Line 105: | Line 103: | ||
|- | |- | ||
|Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265078/</ref> | |Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265078/</ref> | ||
| | |[[RCT]], 6 weeks | ||
* baseline 0 mg/day (n=12) | |||
* small 300 mg/day (n=12) | |||
* medium 600 mg/day (n=12) | |||
* high 1200 mg/day (n=12) | |||
| | | | ||
* 48 young and middle-aged recreationally trained runners | * 48 young and middle-aged recreationally trained runners | ||
| Line 119: | Line 115: | ||
* The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | * The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | ||
* The improvement is muscle, not cardiac, related. | * The improvement is muscle, not cardiac, related. | ||
|- | |||
|The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735188/</ref> | |||
|[[RCT]], 60 days | |||
* placebo (n=20) | |||
* 300 mg (n=20) | |||
* 600 mg (n=20) | |||
* 900 mg (n=20) | |||
| | |||
* both males and females | |||
* 40-65 (49.3 in average) years and healthy | |||
* BMI between 18.5 and 35 | |||
| | |||
* Oral administration of NMN up to 900 mg/day for 60 days was safe and well tolerated | |||
* blood NAD concentration was significantly and dose-dependently increased | |||
* significant improvement of six-minute walking test, blood biological age, and SF-36 scores | |||
* 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | |||
|} | |} | ||